2.68
+0.115(+4.49%)
Currency In USD
| Previous Close | 2.56 |
| Open | 2.58 |
| Day High | 2.73 |
| Day Low | 2.56 |
| 52-Week High | 6.33 |
| 52-Week Low | 2.01 |
| Volume | 2.68M |
| Average Volume | 5.48M |
| Market Cap | 399.97M |
| PE | -2.82 |
| EPS | -0.95 |
| Moving Average 50 Days | 2.86 |
| Moving Average 200 Days | 3.18 |
| Change | 0.12 |
If you invested $1000 in Absci Corporation (ABSI) since IPO date, it would be worth $123.9 as of August 22, 2025 at a share price of $2.675. Whereas If you bought $1000 worth of Absci Corporation (ABSI) shares 3 years ago, it would be worth $680.66 as of August 22, 2025 at a share price of $2.675.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
GlobeNewswire Inc.
Aug 07, 2025 6:00 AM GMT
Almirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci’s successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCO
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
GlobeNewswire Inc.
Jul 30, 2025 8:05 PM GMT
VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will report busine
Absci Announces Pricing of Public Offering of Common Stock
GlobeNewswire Inc.
Jul 25, 2025 12:45 AM GMT
VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, today announced the pricing of an